Go to the list of all blogs
Anna G's Avatar
published in Blogs
Dec 08, 2022
TickeronGET DAILY SIGNALS
Verint (VRNT, $37.04) tops earnings expectations; lowers revenue outlook

Verint (VRNT, $37.04) tops earnings expectations; lowers revenue outlook

Verint Systems reported quarterly adjusted earnings of $0.69 per share, which exceeded the Zacks Consensus Estimate of $0.58 per share (according to Zacks Equity Research). This compares to earnings of $0.69 per share a year ago.

Revenues of $225.62 million (vs. $226.93 million in the year-ago quarter) missed the Zacks Consensus Estimate by 0.80%. (according to Zacks Equity Research).

The company now expects revenue for the year ending Jan. 31 of about $900 million, vs.  prior forecast of $920 million.

Related Ticker: VRNT
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of analytic software solutions for communications interception, digital video security and surveillance, and enterprise business intelligence

Industry ComputerCommunications

Industry
Information Technology Services
Address
175 Broadhollow Road
Phone
+1 631 962-9600
Employees
3700
Web
https://www.verint.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.
Consensus estimates call for Q3 FY2026 revenue of approximately $3.37 billion, in line with the company's guidance midpoint of $3.35 billion. Non-GAAP earnings per share (EPS) expected at $9.16, edging above the guided midpoint of $9.08.